<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545308</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01-01</org_study_id>
    <nct_id>NCT03545308</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Rocuronium for Deep Block (DeepRocu)</brief_title>
  <acronym>DeepRocu</acronym>
  <official_title>Pharmacokinetics of Rocuronium (1 mg/kg) for Deep Block : a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rocuronium is a non-depolarising neuromuscular blocking agent. The compound has a rapid onset
      and an intermediate duration of action.

      The rapid onset is of importance in patients at risk for pulmonary aspiration, for elective
      induction of anesthesia. Clinical studies simulating rapid sequence induction in elective
      patients indicate that rocuronium 0.9 mg kg-1 may be suitable for crash intubation.Also,
      rocuronium may be an alternative to succinylcholine for rapid sequence induction when high
      dose is injected (3x Effective Dose 95 %= 1mg/kg). But, pharmacokinetic of rocuronium at 1
      mg/kg is not well establish.

      The investigator investigate the onset and recovery of a single dose rocuronium (1 mg/kg) in
      consecutive patients (&gt;100) using adductor muscle monitoring (Train of Four and Post Tetanic
      Count)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, pharmacokinetic of rocuronium at 1 mg/kg will be evaluated at each point of
      Train of Four Response (TOF) and Post Tetanic Count (when TOF=0) troughout the period of
      anesthesia and surgery.

      Time 0 is the time of rocuronium injection, Time 1 is the time when post tetanic count is &gt;
      5-7 and TOF=0, Time 3 when TOF &gt;0 response, Time 4 when 4 reponses of the TOF and Time 5 when
      TOF &gt; 90 %
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2017</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Onset</measure>
    <time_frame>3 hour</time_frame>
    <description>The elapsed time (in minute) between Time 0 (injection of rocuronium) to T1 (PTC &gt; 5-7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intubation</measure>
    <time_frame>1 hour</time_frame>
    <description>time for intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Tetanic Count recovery</measure>
    <time_frame>3 hours</time_frame>
    <description>Times between Post Tetanic Count = 0 to 20 (Time 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery Train of Four</measure>
    <time_frame>6 hours</time_frame>
    <description>Times between T0 to train of four= 4 (Time 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antagonization</measure>
    <time_frame>6 hours</time_frame>
    <description>Evaluation of recovery with sugammadex or prostigmine</description>
  </secondary_outcome>
  <enrollment type="Actual">250</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Dose: 1 mg/kg</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for surgery under general anesthesia with the need of deep neuromuscular
        block for surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective or emergency surgery under general anesthesia with deep block

          -  approval

          -  adult

        Exclusion Criteria:

          -  contra indication to neuromuscular blockade (allergy, myopathy, hyperkaliemia)

          -  refusal

          -  &lt; 18 years olds

          -  Body mass index &gt; 50

          -  neuropathy

          -  regional anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>jean-yves lefrant, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Nīmes</investigator_affiliation>
    <investigator_full_name>Philippe Cuvillon</investigator_full_name>
    <investigator_title>Clinical Professor (PhD)</investigator_title>
  </responsible_party>
  <keyword>Neuromuscular</keyword>
  <keyword>Deep Anesthesia</keyword>
  <keyword>Rocuronium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

